Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$62.07 USD
+1.53 (2.53%)
Updated May 3, 2024 04:00 PM ET
After-Market: $62.08 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
EXAS 62.07 +1.53(2.53%)
Will EXAS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EXAS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EXAS
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
EXAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
Other News for EXAS
Exact Sciences to Participate in May Investor Conference
Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
Exact Sciences Announces Board Member Retirement
Artisan Mid Cap Fund Q1 2024 Commentary
Baron Health Care Fund Q1 2024 Shareholder Letter